CTRI/2016/06/006980
Recruiting
Phase 3
Mifepristone and Misoprostol for the termination of pregnancies of 10-20 wks (64-140 days) gestation/in Thailand of 10-14 weeks (64-104 days) gestation
Concept foundation0 sites670 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Healthy subjects coming for abortions
- Sponsor
- Concept foundation
- Enrollment
- 670
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •good general health
- •\-older than the age of legal consent,if her age is younger than age of legal consent,parent should sign informed consent together with volunteer. There is no upper limit and study sites may have different minimum age limits.
- •\-requesting abortion and eligible for legal termination of pregnancy
- •\-on Day 1 of the study (day of mifepristone administration) the duration of pregnancy between 64\-140 days, \- 64\-104 days LMP in Thailand \- verified by ultrasound
- •\-the pregnancy is single and intrauterine (single sac)
- •\-if treatment with the proposed regimen should fail agrees to be treated with the method used at the clinic routinely in this kind of cases
- •\-willing and able to participate after the study has been explained
- •\-haemoglobin higher than 90 g/l.
- •Volunteers live within reasonable distance from hospital premises.
Exclusion Criteria
- •allergy towards mifepristone or misoprostol
- •\- history or evidence of disorders that represent a contraindication to the use of mifepristone (chronic adrenal failure, severe asthma uncontrolled by corticosteroid therapy, inherited porphyria) or prostaglandins (mitral stenosis, sickle cell anaemia, uncontrolled hypertension, systolic blood pressure lower than 90 mmHg measured with a traditional instrument)
- •\- a history or evidence of thrombo\-embolism, severe or recurrent liver disease
- •\- has a medical condition or disease that requires special treatment, care or precaution (e.g. corticosteroid or anticoagulant therapy) in conjunction with abortion
- •\- the presence of an IUD in utero
- •\-previous surgery of uterus/uterine cervix is a relative contraindication. However, one previous low\-segment caesarean section does not need to be a contra\-indication
- •\-molar pregnancy or threatened abortion
- •\-in case difficulties are anticipated in the follow\-up of the woman.
- •Women older than 35 years can be recruited for the present trial provided they do not smoke, their diastolic blood pressure is \< 90mmHg and have no known risk factors for cardiovascular disease.
- •Women who breastfeed can be included but they may discard the breast milk on the day of mifepristone administration.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days GestationMedical; Abortion, FetusNCT01966874Gynuity Health Projects1,001
Active, not recruiting
Phase 1
Comparing two medical treatments for early pregnancy failure.Early pregnancy failureTherapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2017-002694-19-NLRadboud University Medical Centre460
Active, not recruiting
Phase 1
The comparison of two drug treatments for miscarriageWomen aged above 18 years with early pregnancy failure, 6-14 weeks postmenstrual.MedDRA version: 19.0Level: LLTClassification code 10068522Term: Non-surgical treatmentSystem Organ Class: 100000004865MedDRA version: 19.0Level: LLTClassification code 10027650Term: Miscarriage of pregnancySystem Organ Class: 100000004868Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2013-001554-10-NLRadboudumc
Completed
Not Applicable
M&M TrialNL-OMON21883Radboudumc791 Verloskunde & Gynaecologie StafafdelingPostbus 9101, 6500 HB Nijmegen40
Recruiting
Phase 4
TWO DOSES OF MIFEPRISTONE FOLLOWED BY MISOPROSTOL FOR MEDICAL TERMINATION OF PREGNANCY IN THE SECOND TRIMESTERCTRI/2017/12/010862PGIMER